CLINICAL_TRIALS
trial_result
· 2016-12-02
Clinical Trial Update: GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia [Phase 3]
Summary
A Phase 3 trial comparing belimumab to placebo over 52 weeks in systemic lupus erythematosus completed, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2016-12-02